Recruiting

Biological Allograft

Sponsor:

Lenoss Medical

Code:

NCT04064710

Conditions

Vertebral Body Compression Fracture(s)

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Interventions

Vertebral Body Augmentation

Manual Surgical Instruments

Study Details

Brief summary:

A prospective, multi-center study evaluating allograft tissue as a bone void filler when implanted with Lenoss Medical manual surgical instrumentation in patients with painful vertebral compression fractures.

Conditions

Vertebral Body Compression Fracture(s)

Study ID

NCT04064710

Start date

Jun 10, 2019

Status verified date

May, 2021

Completion date

Dec 1, 2022

Anticipated

Primary completion date

Aug 1, 2022

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Skeletally mature adult ≥ 50 years of age at the time of surgery;
2. Currently in an independent living environment;
3. One- or two- level, acute (within six weeks of injury), thoracic or lumbar (T6-L5) vertebral body compression fracture(s) with evidence of marrow edema by MRI/CT;
4. Adequate vertebral body height and geometry for insertion of the access instruments, as determined by the investigator and suitable candidate for standard kyphoplasty or vertebroplasty procedure;
5. VAS back pain score ≥ 70 mm on a 100 mm scale;
6. Has central pain over the spinous process upon palpation at the planned vertebral index level;
7. Has failed prior non-surgical medical management (i.e. - physical therapy, narcotic and/or non-narcotic medication)
8. Psychosocially, mentally and physically able to fully comply with this protocol including adhering to scheduled visits, treatment plan, completing forms, and other study procedures;
9. Personally signed and dated informed consent document prior to any study-related procedures indicating that the patient has been informed of all pertinent aspects of the study.

Exclusion Criteria:

1. More than two levels with a vertebral compression fracture;
2. Previous treated or untreated vertebral compression fracture at the to be treated level(s);
3. Uncorrectable coagulopathy;
4. Previous instrumented spinal surgery;
5. Significant vertebral collapse defined as > 70% of original vertebral height, or a burst, or pedicle fracture;
6. Degenerative scoliosis, defined as Cobb angle > 20° at any level;
7. Pre-existing neurological deficit or radicular pain that is not well defined or unstable;
8. Disabling back pain secondary to causes other than acute fracture;
9. Inability to walk or stand prior to sustaining the vertebral compression fracture;
10. Active systemic or local infection;
11. Known history of Paget's disease, osteomalacia, or any other metabolic bone disease;
12. Morbid obesity defined as a body mass index > 40 kg/m2;
13. Active malignancy. A patient with a history of any invasive malignancy (except nonmelanoma skin cancer), unless treated with curative intent and there has been no clinical signs or symptoms of the malignancy for more than 5 years;
14. Current or recent history (within last 2 years) of substance abuse (e.g., recreational drugs, narcotics, or alcohol);
15. Currently involved in study of another investigational product that may affect outcome;
16. History of psychosocial disorders that could prevent accurate completion of self reporting assessment scales;
17. Pregnant or planning to become pregnant during the study period;
18. Involved in active spinal litigation;
19. Involved in a workers compensation case;
20. Prisoner or ward of the state;
21. Unable to undergo a MRI/CT procedure.

Study Design

Enrollment

26 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

other: Allograft Tissue

Allograft tissue product for patients with painful vertebral compression fractures

Interventions

Vertebral Body Augmentation

Use allograft tissue in patients with one or two level, thoracic or lumbar T6-L5, vertebral compression fractures.

Manual Surgical Instruments

Lenoss Medical manual surgical access and cavity creation instruments will be used when implanting the allograft tissue.

Primary outcome measure

  • Evaluate fracture stability assessed via subject- reported pain over time [ Time Frame: 12 months ]

Central Contacts and Locations

Central contacts

Locations

University of Colorado Denver | Anschutz Medical Campus

Recruiting

Denver, Colorado, United States, 80204

Contacts

Principal Investigator:

Corey Ho, MD

Montefiore Medical Center

Recruiting

Bronx, New York, United States, 10467

Contacts

Principal Investigator:

Allan Brook, MD

North Shore University Hospital

Recruiting

Manhasset, New York, United States, 11030

Contacts

Principal Investigator:

Athos Patsalides, MD

Mount Sinai

Recruiting

New York, New York, United States, 10029

Contacts

Principal Investigator:

Reade De Leacy, MD

More Information

Sponsor

Lenoss Medical

Last update posted

May 14, 2021

Last verified

May, 2021

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Lenoss Medical on 2021-05-14.